规格 | 价格 | 库存 | 数量 |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
化合物 1,或称卡洛芬,是一种非甾体类抗炎药。作为 FAAH/COX 的多靶点抑制剂,COX-2、COX 和 FAAH 的 IC50 值分别为 3.9 μM、22.3 μM 和 78.6 μM-1。在 CCL 和 CaCL 细胞中,卡洛芬 (10 μg/mL) 具有细胞保护特性并降低细胞凋亡。与相应的 CCL 或 CaCL 对照相比,卡洛芬 (10 μg/mL) 并未显着增加 PGE2 浓度 [2]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
第 3 天和第 10 天,卡洛芬(2.2 mg/kg,口服)显着降低了犬血液中 PGE2 的水平。第三天,卡洛芬同样减少了胃中 PGE2 的合成;然而,到了第 10 天,抑制作用就没那么大了。此外,在第3天和第10天,证明卡洛芬对狗胃内PGE1的合成没有影响[3]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Favia AD, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26.
[2]. Waldherr K, et al. In vitro cytoprotective effects of acetylsalicylic acid, carprofen, meloxicam, or robenacoxib against apoptosis induced by sodium nitroprusside in canine cruciate ligament cells. Am J Vet Res. 2012 Nov;73(11):1752-8. [3]. Sessions JK, et al. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res. 2005 May;66(5):812-7 |
分子式 |
C15H12CLNO2
|
|
---|---|---|
分子量 |
273.71
|
|
CAS号 |
53716-49-7
|
|
相关CAS号 |
Carprofen-d3;1173019-42-5;Carprofen-13C,d3;2012598-34-2
|
|
外观&性状 |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
ClC1C([H])=C([H])C2=C(C=1[H])C1C([H])=C([H])C(=C([H])C=1N2[H])C([H])(C(=O)O[H])C([H])([H])[H]
|
|
InChi Key |
PUXBGTOOZJQSKH-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
|
|
化学名 |
2-(6-chloro-9H-carbazol-2-yl)propanoic acid
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
配方 1 中的溶解度: ≥ 2.08 mg/mL (7.60 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 20.8 mg/mL澄清DMSO储备液加入400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.08 mg/mL (7.60 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.08 mg/mL (7.60 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6535 mL | 18.2675 mL | 36.5350 mL | |
5 mM | 0.7307 mL | 3.6535 mL | 7.3070 mL | |
10 mM | 0.3654 mL | 1.8268 mL | 3.6535 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06420323 | Not yet recruiting | Device: Treatment with NovoX® Cup Device: Treatment with Omnistrip® |
Wound Healing Disorder Post-Surgical Complication Mammaplasty |
MOSS S.p.A. | June 2024 | |
NCT06458478 | Recruiting | Other: Hyper-oxygenated gel Other: glycerin based gel |
Molar, Fourth Extracting Own Teeth Edema Face (and 2 more...) |
Azienda Ospedaliera di Perugia | July 1, 2024 | Not Applicable |
NCT03911336 | Withdrawn | Drug: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID Drug: Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID Drug: Group C - Control 2: tooth extraction and intake of a Non-Nsaid |
Tooth Loss | University of Iowa | January 1, 2023 | Phase 4 |
NCT01448785 | Unknown † | Device: abiliti system implant Device: Laparoscopic adjustable gastric band (Allergan Lap Band) |
Obesity Morbid Obesity |
IntraPace, Inc | April 2011 | Not Applicable |
Circular tree based on pairwise Tanimoto distances between Daylight fingerprints of 382 diverse known COXs inhibitors. To help in the interpretation, only selected molecules, belonging to different clusters, are depicted in proximity of their positions in the tree to highlight the structural diversity of the set. Carprofen is shown in the upper left corner.[1]Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26. td> |
Tree based on the pairwise Tanimoto-fingerprint distances between the 25 COX inhibitors tested in the present study. The heat map highlights the distances calculated in the first 5 principal components space (% variance explained > 90%) originating from 10 physico-chemical descriptors (i.e. net charge, MW, LogP, LogS, HBD, HBA, PSA, no. of atoms, no. of rings and no. of rotatable bonds).[1]Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26. td> |
Synthesis of compounds 6, 8, 10 and 12aaReagents and conditions: (a) R1-X, Cs2CO3, MeCN, reflux, 12 h, 32-99 %; (b) R2-SO2Cl, Et3N, DMAP, THF, reflux, 5 h or 100 °C, 3 h, MW, 35-78 %; (c) R3-NCO, Et3N, DMAP, THF, 100 °C, MW, 10 h, 51-81 %; (d) LiOH, MeOH, THF, H2O, 12 h, 21-85%; (e) 6M HCl, THF, rt, 5 days, 80 %; (f) hexyl chloroformate, Et3N, DMAP, THF, 100 °C, 3 h, MW, 85 %; (g) 6M HCl, THF, rt, 3 days, 55 %.[1]Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26. td> |